An-Najah Staff

Abstract: Objective: To investigate differences in medication adherence, treatment satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic treatment regimens. Methodology: Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) while treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were measured using the 24-item expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and analyzed using SPSS 16 for windows. Results: A convenience sample of 131 schizophrenic patients was studied. Patients belonged to 7 groups based on their antipsychotic treatment regimens. There was no significant difference in the means of adherence (P=0.6) and BPRS domains: positive (P=0.6), negative (P=0.8), manic (P=0.2) and depression (P=0.9) scores among the studied groups. Satisfaction with side effect domain was significantly different among studied groups (P=0.006, F=3). However, no significant difference was found in other satisfaction domains: effectiveness (P=0.8), convenience (P=0.3), and global satisfaction (P=0.8). Conclusions: Medications adherence, most treatment satisfaction domains and clinical symptom scores were not significantly different among patients taking different antipsychotic regimens.

Aims The main aims of the study were to investigate the prevalence of pre-diabetes and diabetes mellitus (DM) in patients with schizophrenia, to compare it with those published in the general population, and to assess significant associations with dysglycemia defined as having either pre-DM or DM.
Methods A cross-sectional study carried out in 4 governmental primary psychiatric healthcare centers in Northern West-Bank, Palestine. Fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) were measured. The World Health Organization (WHO) criteria for defining pre-DM and DM were used. Dysglycemia was defined as FBG >110 mg/dl.
Results Based on WHO criteria, 27 patients (10.8%) had diabetes and 34 (13.6%) had pre-diabetes. The prevalence of DM in patients with schizophrenia was not significantly higher than that reported in the general population of Palestine. However, the prevalence of pre-DM was significantly higher than that reported in the general population of Palestine. Regression analysis showed that advancing age and abnormal waist circumference were significant predictors of dysglycemia in patients with schizophrenia.
Conclusions This study confirmed the high prevalence of dysglycemia in patients with schizophrenia, supporting the need for monitoring of blood glucose in this category of patients. The presence of primary risk factors is more important in the development of dysglycemia in patients with schizophrenia than exposure to antipsychotic drugs.  

Background: In Arab and Muslim-dominated countries, spirituality and religiosity shape the belief and practices toward chronic illnesses. No previous studies were published to assess adherence to and satisfaction with antipsychotic medications in persons with schizophrenia in the Arab world.
Objective: To assess medication adherence and treatment satisfaction with antipsychotics in a sample of Palestinian people with schizophrenia. Methodology: Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for windows. Results: A convenience sample of 131 persons with schizophrenia was studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly correlated (P=0.028) with adherence score. However, variables like use of monotherapy or atypical or depot antipsychotics were not significantly associated with higher adherence. The means of satisfaction with regard to effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5, 67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant difference in the means of effectiveness (P < 0.01), convenience (P < 0.01), global satisfaction (P < 0.01), but not side effects domains (P=0.1) among persons with different levels of adherence. Furthermore, there was a significant difference in the means of positive symptom score (P < 0.01), manic (P < 0.01) and depression (P < 0.01) but not negative symptom score (P=0.4) among persons with different levels of adherence.
Conclusions: Medication nonadherence was common and was associated with low treatment satisfaction scores and poor psychiatric scores. Medication related factors had insignificant effects on adherence scores

OBJECTIVE: To investigate differences in medication adherence, treatment satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic treatment regimens.
METHODOLOGY: Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) while treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were measured using the 24-item expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and analyzed using SPSS 16 for windows.
RESULTS: A convenience sample of 131 schizophrenic patients was studied. Patients belonged to 7 groups based on their antipsychotic treatment regimens. There was no significant difference in the means of adherence (P=0.6) and BPRS domains: positive (P=0.6), negative (P=0.8), manic (P=0.2) and depression (P=0.9) scores among the studied groups. Satisfaction with side effect domain was significantly different among studied groups (P=0.006, F=3). However, no significant difference was found in other satisfaction domains: effectiveness (P=0.8), convenience (P=0.3), and global satisfaction (P=0.8).
CONCLUSIONS: Medications adherence, most treatment satisfaction domains and clinical symptom scores were not significantly different among patients taking different antipsychotic regimens.